The "other site" admin decided that my Naked Shorting

New Post Public Reply Private Reply Replies (2) Message Board

May 27, 2018 at 8:43 AM 592

The "other site" admin decided that my Naked Shorting official data post is now off topic.... By doing this, they have removed one of my post during my probationary period.

Quote:

The bad guys want to silence me as I continue to educate our investors how bad and illegally ANDI is being shorted on a daily basis.

Bad guys are allowed to short 25% of the daily volume and must not take a stock down more than 10% of its value in 1 trading day.

Typically the bad guys are shorting 50% or more of the daily volume. FACT

This is my post that the other site decided to remove as off topic and further continue my restriction to 1 post:
STOP the NAKED SHORTING and MANIPULATION of ANDI
UPDATED as of 5/26/18

Quote:

DAILY EVIDENCE IS BEING RECORDED!!!

Dose this sound like what is happening at ANDI ? Yes it does! Great read here. A Must read!!!
https://www.linkedin.com/pulse/share-intel-so...is-o-neill

Quote:

The chart doesn't say "pump and dump" it says NAKED shorted to death!

Quote:

Short volume and total volume ANDI 5/07/18

NAKED SHORTING RED FLAGS. EXCESSIVE RED FLAGS. SOUND THE ALARMS RED FLAGS

20180507|ANDI|18004445|0|41161947|O
(breakdown)
Short volume: 18,004,445
Total volume: 41,161,947

Quote:

percentage shorted: 44%

Source: http://regsho.finra.org/FORFshvol20180507.txt

Quote:

Short volume and total volume ANDI 5/08/18

20180508|ANDI|42382762|0|65151212|O
(breakdown)
Short volume: 42,382,762
Total volume: 65,151,212

Quote:

percentage shorted: 65%

Source: http://regsho.finra.org/FORFshvol20180508.txt

Quote:

Short volume and total volume ANDI 5/09/18

20180509|ANDI|57462223|0|74932212|O
(breakdown)
Short volume: 57,462,223
Total volume: 74,932,212

Quote:

percentage shorted: 77%

Source: http://regsho.finra.org/FORFshvol20180509.txt

Quote:

Short volume and total volume ANDI 5/10/18

20180510|ANDI|27682509|0|52957800|O
(breakdown)
Short volume: 27,682,509
Total volume: 52,957,800

Quote:

percentage shorted: 52%

Source: http://regsho.finra.org/FORFshvol20180510.txt

Quote:

Short volume and total volume ANDI 5/11/18

20180511|ANDI|15884329|0|37635260|O
(breakdown)
Short volume: 15,884,329
Total volume: 37,635,260

Quote:

percentage shorted: 42%

Source: http://regsho.finra.org/FORFshvol20180511.txt

Quote:

Short volume and total volume ANDI 5/14/18

20180514|ANDI|7933686|0|21316691|O
(breakdown)
Short volume: 7,933,686
Total volume: 21,316,691

Quote:

percentage shorted: 37%

Source: http://regsho.finra.org/FORFshvol20180514.txt

Quote:

Short volume and total volume ANDI 5/15/18

20180515|ANDI|13708100|0|24536708|O
(breakdown)
Short volume: 13,708,100
Total volume: 24,536,708

Quote:

percentage shorted: 56%

Source: http://regsho.finra.org/FORFshvol20180515.txt

Quote:

Short volume and total volume ANDI 5/16/18

20180516 |ANDI| 19899204 |0| 38028150 |O
(breakdown)
Short volume: 19,899,204
Total volume: 38,028,150

Quote:

ANDI percentage shorted: 52%

source: http://regsho.finra.org/FORFshvol20180516.txt

Quote:

Short volume and total volume ANDI 5/18/18

20180518|ANDI|5697743|0|14964082|O
(breakdown)
Short volume: 5,697,743
Total volume: 14,964,082

Quote:

ANDI percentage shorted: 38%

http://regsho.finra.org/FORFshvol20180518.txt

Quote:

Short volume and total volume ANDI 5/21/18

20180521|ANDI|4856041|0|12361132|O
(breakdown)
Short volume: 4,856,041
Total volume: 12,361,132

Quote:

ANDI percentage shorted: 39%

http://regsho.finra.org/FORFshvol20180521.txt

Quote:

Short volume and total volume ANDI 5/22/18

20180522|ANDI|24447684|0|57265411|O
(breakdown)
Short volume: 24,447,684
Total volume: 57,265,411

Quote:

percentage shorted: 43%

http://regsho.finra.org/FORFshvol20180522.txt

Quote:

Short volume and total volume ANDI 5/23/18

20180523|ANDI|54206498|0|103131419|O
(breakdown)
Short volume: 54,206,498
Total volume: 103,131,419

Quote:

percentage shorted: 53%

http://regsho.finra.org/FORFshvol20180523.txt

Quote:

Short volume and total volume ANDI 5/24/18

20180524|ANDI|36362727|0|65305878|O
(breakdown)
Short volume: 36,362,727
Total volume: 65,305,878

Quote:

percentage shorted: 57%

Source: http://regsho.finra.org/FORFshvol20180524.txt

Quote:

Short volume and total volume ANDI 5/25/18

20180525|ANDI|30358431|0|51383461|O
(breakdown)
Short volume: 30,358,431
Total volume: 51,383,461

Quote:

percentage shorted: 59%

Source: http://regsho.finra.org/FORFshvol20180525.txt

Quote:

Specifically, the Rule requires that a trading center establish, maintain, and enforce written policies and procedures reasonably designed to prevent the execution or display of a short sale order of a covered security at a price that is less than or equal to the current national best bid if the price of that covered security decreases by 10% or more from the covered security’s closing price as determined by the listing market for the covered security as of the end of regular trading hours on the prior day.

source: https://www.sec.gov/rules/final/2010/34-61595.pdf
NAKED SHORTERS RED FLAGS
GAP trap 5/9/18 was so unethically wrong...

"The Stewy"

Andiamo Corp (ANDI) Stock Research Links

ANDI Board Company Profile Buy Rating Time & Sales News Filings Financials

"The Stewy"

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

2026 Community Impact Week: Slam Dunk for Community Unity

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

LEGO Mashes Star Wars and Marvel for Fans' Delight

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Duolingo Faces Lawsuit Over Alleged Investor Missteps

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...